Trial
NCT04145700
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Synovial Sarcoma
Intervention
Ramucirumab
Why stopped
Study terminated for meeting protocol specified futility criteria.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-09-13